Oscar Arrieta1, Julissa Luvián-Morales1, Jenny G Turcott1, Luis F Oñate-Ocaña2. 1. Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. 2. Clinical Research Division, Instituto Nacional de Cancerología de México (INCan), San Fernando #22, Col. Sección XVI, Tlalpan, 14080, Mexico City, Mexico. lfonate@gmail.com.
Abstract
PURPOSE: The cancer anorexia-cachexia syndrome (CACS) is highly prevalent in lung cancer (LC) patients (57-61%), and represents the direct cause of death in 20% of cases. Accurately quantifying CACS has been a challenging issue; consequently, this study presents the clinical validation of the Spanish version of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in LC patients from Latin America. METHODS: The Spanish version of the FAACT and the Mexican-Spanish version of the EORTC-QLQ-C30 instruments were applied to a cohort of patients with LC at the National Cancer Institute of Mexico. Reliability and validity tests were performed to assess the psychometric properties of the scales, and clinical validation was assessed considering the association of scales with subjective and objective clinical data. RESULTS: Two hundred patients were included. Questionnaire compliance rates were high (100%) and the instrument was well accepted in all cases; internal consistency tests demonstrated good convergent and divergent validity of the scale structure. Cronbach's α coefficient for three out of five basic multi-item scales was > 0.7 (0.55-0.86). FAACT scales presented significant associations with clinical parameters, including biochemical and nutritional variables (i.e., energy intake, p = 0.002), as well as strongly correlated with the appetite loss subscale of the QLQ-C30 questionnaire (r = - 0.624). Physical well-being (p < 0.0009), functional well-being (p = 0.004), anorexia/cachexia scale (p = 0.029), and FAACT total scores (p = 0.0009) were strongly associated to overall survival. CONCLUSION: The Spanish version of the FAACT questionnaire is reliable and valid for the assessment of health-related quality of life and CACS in LC patients and can be used in clinical trials.
PURPOSE: The cancer anorexia-cachexia syndrome (CACS) is highly prevalent in lung cancer (LC) patients (57-61%), and represents the direct cause of death in 20% of cases. Accurately quantifying CACS has been a challenging issue; consequently, this study presents the clinical validation of the Spanish version of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in LC patients from Latin America. METHODS: The Spanish version of the FAACT and the Mexican-Spanish version of the EORTC-QLQ-C30 instruments were applied to a cohort of patients with LC at the National Cancer Institute of Mexico. Reliability and validity tests were performed to assess the psychometric properties of the scales, and clinical validation was assessed considering the association of scales with subjective and objective clinical data. RESULTS: Two hundred patients were included. Questionnaire compliance rates were high (100%) and the instrument was well accepted in all cases; internal consistency tests demonstrated good convergent and divergent validity of the scale structure. Cronbach's α coefficient for three out of five basic multi-item scales was > 0.7 (0.55-0.86). FAACT scales presented significant associations with clinical parameters, including biochemical and nutritional variables (i.e., energy intake, p = 0.002), as well as strongly correlated with the appetite loss subscale of the QLQ-C30 questionnaire (r = - 0.624). Physical well-being (p < 0.0009), functional well-being (p = 0.004), anorexia/cachexia scale (p = 0.029), and FAACT total scores (p = 0.0009) were strongly associated to overall survival. CONCLUSION: The Spanish version of the FAACT questionnaire is reliable and valid for the assessment of health-related quality of life and CACS in LC patients and can be used in clinical trials.
Entities:
Keywords:
Anorexia; CACS; Cachexia; Lung cancer; Malnutrition; Quality of life
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: D Blum; G B Stene; T S Solheim; P Fayers; M J Hjermstad; V E Baracos; K Fearon; F Strasser; S Kaasa Journal: Ann Oncol Date: 2014-02-20 Impact factor: 32.976
Authors: Óscar Arrieta; Carolina Núñez-Valencia; Leonardo Reynoso-Erazo; Salvador Alvarado; Diana Flores-Estrada; Laura Patricia Angulo; Luis F Oñate-Ocaña Journal: Lung Cancer Date: 2012-03-03 Impact factor: 5.705
Authors: Karla Sánchez-Lara; Jenny G Turcott; Eva Juárez; Patricia Guevara; Carolina Núñez-Valencia; Luis F Oñate-Ocaña; Diana Flores; Oscar Arrieta Journal: Nutr Cancer Date: 2012-04-10 Impact factor: 2.900
Authors: M Muscaritoli; S D Anker; J Argilés; Z Aversa; J M Bauer; G Biolo; Y Boirie; I Bosaeus; T Cederholm; P Costelli; K C Fearon; A Laviano; M Maggio; F Rossi Fanelli; S M Schneider; A Schols; C C Sieber Journal: Clin Nutr Date: 2010-01-08 Impact factor: 7.324
Authors: Richard J E Skipworth; Grant D Stewart; Cornelis H C Dejong; Tom Preston; Kenneth C H Fearon Journal: Clin Nutr Date: 2007-05-15 Impact factor: 7.324
Authors: John M Salsman; Jennifer L Beaumont; Katy Wortman; Ying Yan; John Friend; David Cella Journal: Support Care Cancer Date: 2014-10-29 Impact factor: 3.603
Authors: Jenny G Turcott; María Del Rocío Guillen Núñez; Diana Flores-Estrada; Luis F Oñate-Ocaña; Zyanya Lucia Zatarain-Barrón; Feliciano Barrón; Oscar Arrieta Journal: Support Care Cancer Date: 2018-03-17 Impact factor: 3.603